Naing C, Aung H, Aye S, Poovorawan Y, Whittaker M
PLoS One. 2024; 19(8):e0307172.
PMID: 39173001
PMC: 11341061.
DOI: 10.1371/journal.pone.0307172.
Chen X, Keller S, Hafner P, Alrawashdeh A, Avery T, Norona J
Front Immunol. 2024; 15:1340726.
PMID: 38504984
PMC: 10948527.
DOI: 10.3389/fimmu.2024.1340726.
Tojjari A, Saeed A, Sadeghipour A, Kurzrock R, Cavalcante L
Cancers (Basel). 2023; 15(22).
PMID: 38001644
PMC: 10670368.
DOI: 10.3390/cancers15225384.
Teoh Y, Jiang J, Yamasaki T, Nagata N, Sugawara T, Hasebe R
Front Vet Sci. 2023; 10:1192888.
PMID: 37519997
PMC: 10375717.
DOI: 10.3389/fvets.2023.1192888.
Yan H, Jiang M, Yang F, Tang X, Lin M, Zhou C
Molecules. 2022; 27(17).
PMID: 36080236
PMC: 9457730.
DOI: 10.3390/molecules27175469.
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma.
Vo J, Wu Y, Mishler J, Hall S, Mannan R, Wang L
Nat Commun. 2022; 13(1):3750.
PMID: 35768438
PMC: 9243087.
DOI: 10.1038/s41467-022-31430-0.
Protein tyrosine phosphatases in skeletal development and diseases.
Yang H, Wang L, Shigley C, Yang W
Bone Res. 2022; 10(1):10.
PMID: 35091552
PMC: 8799702.
DOI: 10.1038/s41413-021-00181-x.
Making sense of IL-6 signalling cues in pathophysiology.
Millrine D, Jenkins R, Hughes S, Jones S
FEBS Lett. 2021; 596(5):567-588.
PMID: 34618359
PMC: 9673051.
DOI: 10.1002/1873-3468.14201.
SOCS Proteins in Immunity, Inflammatory Diseases, and Immune-Related Cancer.
Sobah M, Liongue C, Ward A
Front Med (Lausanne). 2021; 8:727987.
PMID: 34604264
PMC: 8481645.
DOI: 10.3389/fmed.2021.727987.
Targeted Ptpn11 deletion in mice reveals the essential role of SHP2 in osteoblast differentiation and skeletal homeostasis.
Wang L, Yang H, Huang J, Pei S, Wang L, Feng J
Bone Res. 2021; 9(1):6.
PMID: 33500396
PMC: 7838289.
DOI: 10.1038/s41413-020-00129-7.
IL-6 in inflammation, autoimmunity and cancer.
Hirano T
Int Immunol. 2020; 33(3):127-148.
PMID: 33337480
PMC: 7799025.
DOI: 10.1093/intimm/dxaa078.
The JAK1/STAT3/SOCS3 axis in bone development, physiology, and pathology.
Sims N
Exp Mol Med. 2020; 52(8):1185-1197.
PMID: 32788655
PMC: 8080635.
DOI: 10.1038/s12276-020-0445-6.
Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome.
Beziat V, Tavernier S, Chen Y, Ma C, Materna M, Laurence A
J Exp Med. 2020; 217(6).
PMID: 32207811
PMC: 7971136.
DOI: 10.1084/jem.20191804.
Targeting STAT-3 signaling pathway in cancer for development of novel drugs: Advancements and challenges.
Arshad S, Naveed M, Ullia M, Javed K, Butt A, Khawar M
Genet Mol Biol. 2020; 43(1):e20180160.
PMID: 32167126
PMC: 7198026.
DOI: 10.1590/1678-4685-GMB-2018-0160.
SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling.
Niogret C, Birchmeier W, Guarda G
Front Immunol. 2019; 10:2468.
PMID: 31708921
PMC: 6823243.
DOI: 10.3389/fimmu.2019.02468.
IL-6-PAD4 axis in the earliest phase of arthritis in knock-in gp130F759 mice, a model for rheumatoid arthritis.
Yahagi A, Saika T, Hirano H, Takai-Imamura M, Tsuji F, Aono H
RMD Open. 2019; 5(2):e000853.
PMID: 31321075
PMC: 6606081.
DOI: 10.1136/rmdopen-2018-000853.
Regulation of Brain-Derived Neurotrophic Factor and Growth Factor Signaling Pathways by Tyrosine Phosphatase Shp2 in the Retina: A Brief Review.
Abbasi M, Gupta V, Chitranshi N, You Y, Dheer Y, Mirzaei M
Front Cell Neurosci. 2018; 12:85.
PMID: 29636665
PMC: 5880906.
DOI: 10.3389/fncel.2018.00085.
Th17 in Animal Models of Rheumatoid Arthritis.
Hashimoto M
J Clin Med. 2017; 6(7).
PMID: 28753982
PMC: 5532581.
DOI: 10.3390/jcm6070073.
Cryptotanshinone inhibits human glioma cell proliferation in vitro and in vivo through SHP-2-dependent inhibition of STAT3 activation.
Lu L, Zhang S, Li C, Zhou C, Li D, Liu P
Cell Death Dis. 2017; 8(5):e2767.
PMID: 28492557
PMC: 5520699.
DOI: 10.1038/cddis.2017.174.
Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update.
Su H, Lei C, Zhang C
Front Immunol. 2017; 8:405.
PMID: 28484449
PMC: 5399081.
DOI: 10.3389/fimmu.2017.00405.